
Methods: Subjects were enrolled in groups of 20 from 3 serogroups: HSV1+ or -/HSV2+ (group 1), HSV1+/HSV2– (group 2), and HSV1-/HSV2– (group 3). At months 0, 1, and 6, fifteen subjects in each group received HSV529 intramuscularly and 5 subjects received placebo. The primary endpoint was the frequency of solicited injection site and systemic reactions from day 0 to 7 after each vaccination and unsolicited adverse events up to 6 months after the last dose.
Results:
89% of vaccine recipients experienced a mild to moderate solicited injection site reaction versus 47% of placebo recipients (P = 0.006, 95% CI 0.129, 0.676) that did not preclude additional doses. 64% of vaccine recipients experienced solicited systemic reactions versus 53% of placebo recipients (P = 0.44, 95% CI -0.179, 0.402). Two serious adverse events occurred in 2 participants and were assessed as unrelated to HSV529 administration. Serum neutralizing antibody titers significantly increased from baseline after 3 doses of HSV529 compared to placebo in group 3 only (P < 0.001). This increase persisted up to 6 months after the third dose of vaccine (P < 0.001). Serum and vaginal antibodies to HSV2 glycoprotein D (gD) also significantly increased after 3 doses of vaccine in group 3 subjects (P < 0.001 and P = 0.012, respectively). The mean vaginal gD titer after 3 doses was about one-third of the mean serum gD titer. In addition, the vaccine induced significant levels of HSV2-specific antibody dependent cellular cytotoxicity (ADCC) after 3 doses in group 3 subjects compared to placebo (P < 0.001). Vaccine-induced CD4 T-cell responses were detected in 46%, 27%, and 36% of subjects in groups 1, 2, and 3, respectively, one month after the third dose of vaccine. CD8 T-cell responses were detected in 8%, 18%, and 14% of subjects in groups 1, 2, and 3, respectively, at the same time point.
Conclusion: The HSV529 vaccine was safe, well-tolerated, and immunogenic, eliciting significant neutralizing, gD, and ADCC-mediating antibodies, and modest cellular immune responses in HSV seronegative individuals. NCT01915212

L. Dropulic,
Sanofi Pasteur:
Collaborator
,
Research support
M. Oestreich, Sanofi Pasteur: Collaborator , Research support
H. Pietz, Sanofi Pasteur: Collaborator , Research support
D. Garabedian, Sanofi Pasteur: Collaborator , Research support
S. Jegaskanda, None
K. Dowdell, Sanofi Pasteur: Collaborator , Research support
H. Nguyen, Sanofi Pasteur: Collaborator , Research support
K. Laing, Sanofi Pasteur: Research Contractor , payment for conducting T cell assays
D. Koelle, Sanofi Pasteur: Research Contractor , payment for conducting T cell assays
A. Azose, Sanofi Pasteur: Research Contractor , Payment for conducting T cell assays
S. Hunsberger, None
K. Lumbard, None
A. Chen, Sanofi Pasteur: Employee , Salary
L. J. Chang, Sanofi Pasteur: Employee , Salary
S. Phogat, Sanofi Pasteur: Employee , Salary
J. Cohen, None